The global albumin (as excipient) market was valued at US$ 0.81 billion in 2021 and is projected to exceed US$ 1.7 billion by the end of 2031, expanding at a CAGR of 6.3% from 2022 to 2031. Market growth is primarily driven by the increasing number of pharmaceutical and biotechnology companies, along with the rising usage of albumin in drug development and vaccine production.

Access key findings and insights from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3984

Market Overview

Albumin is a multifunctional protein widely used as an excipient in pharmaceutical formulations, vaccine production, drug delivery systems, and medical device coatings. It plays a crucial role in stabilizing active pharmaceutical ingredients (APIs), preventing protein aggregation, and enhancing drug bioavailability.

Albumin is also utilized in diagnostics, in vitro fertilization, cryopreservation, and cell culture applications. Its unique ability to bind with a wide variety of molecules makes it an ideal carrier in advanced drug delivery systems such as albumin-drug nanoparticles, fusion proteins, and pro-drugs.

The market is evolving with a noticeable shift toward recombinant albumin, driven by regulatory guidelines encouraging reduced reliance on animal-derived materials. This transition is particularly significant in biologics and vaccine development, where safety, purity, and consistency are critical.

Key Market Growth Drivers

Rising Usage in Drug Development and Vaccine Production

The increasing use of albumin in drug delivery and vaccine development is a major driver of market growth. Albumin enhances the stability of protein-based therapeutics by protecting them from shear stress, preventing surface adsorption, and providing thermal stability.

Its application in vaccine production, including COVID-19 vaccines, has further strengthened its importance as a reliable excipient. Albumin’s multifunctional properties, including antioxidant activity and protein stabilization, make it indispensable in modern pharmaceutical formulations.

Growth in Pharmaceutical & Biotechnology Industry

The rapid expansion of pharmaceutical and biotechnology companies globally is significantly contributing to the demand for albumin-based excipients. Increased research and development activities aimed at developing advanced therapeutics for chronic diseases such as cancer, diabetes, and hepatitis are further driving market growth.

Additionally, the rising prevalence of liver and kidney diseases is increasing the need for effective drug delivery systems, thereby boosting the adoption of albumin in pharmaceutical applications.

Shift Toward Recombinant Albumin

Regulatory recommendations to minimize the use of animal-derived components have accelerated the adoption of recombinant albumin. This trend is creating new opportunities for manufacturers to develop safer and more consistent excipient solutions for biologics and personalized medicine.

Analysis of Key Players

The global albumin (as excipient) market is consolidated, with key players focusing on innovation, strategic partnerships, and expansion initiatives. Prominent companies include Albumedix Ltd., Albumin Therapeutics, LLC (Albumin Bioscience), Biotest AG, CSL Behring, Grifols, S.A, HiMedia Laboratories, InVitria, Medxbio Pte Ltd., Octapharma AG, RayBiotech, Inc., SeraCare Life Sciences, Sigma-Aldrich Co. (Merck KGaA), and Takeda Pharmaceutical Company Limited (Shire).

Market Challenges & Opportunities

The market faces challenges such as stringent regulatory requirements, high production costs, and concerns related to the sourcing of human serum albumin. Compliance with global safety standards can increase operational complexity for manufacturers.

However, these challenges present opportunities for innovation, particularly in the development of recombinant albumin and synthetic alternatives. The increasing focus on biologics, personalized medicine, and advanced drug delivery systems offers significant growth potential.

Emerging markets, especially in Asia, present lucrative opportunities due to rising healthcare expenditure, growing pharmaceutical manufacturing capabilities, and increasing demand for advanced therapeutics.

Explore our report to uncover in-depth insights – https://www.transparencymarketresearch.com/albumin-market.html

Recent Developments

• In July 2021, Grifols, a global leader in the production of plasma-derived medicines, partnered with the U.S.-based company ImmunoTek Bio Centers LLC to build plasma centers
• In July 2020, Grifols announced an agreement to acquire GC Pharma Group, a biotechnology pioneer in South Korea with a plasma fractionation facility, for around US$ 460 Mn
• In May 2020, Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, introduced ALBUMINEX 5 percent (human albumin) solution and ALBUMINEX 25 percent for the treatment of hypovolemia, ascites, and hypoalbuminemia

Market Segmentation

By Product Type

• Human Serum Albumin (HSA) (Dominant segment)
• Recombinant Albumin

Human serum albumin holds a significant share due to its high stability, effectiveness as a drug delivery vehicle, and wide usage in pharmaceutical and biotech applications. However, recombinant albumin is gaining traction due to regulatory support and improved safety profiles.

By Application

• Drug Delivery (Leading segment)
• Vaccines
• Diagnostics
• Others

The drug delivery segment dominates due to albumin’s superior binding capacity, biodegradability, and non-immunogenic properties, making it ideal for advanced therapeutic systems.

By End-user

• Pharmaceutical & Biotechnology Companies
• Research Institutes
• Others

The pharmaceutical and biotechnology segment accounts for the largest share due to increased demand for advanced drug formulations and biologics.

Regional Outlook

North America (Leading Region – ~38% Share)

North America held the largest share of the global albumin (as excipient) market in 2021. The region’s dominance is attributed to the high prevalence of chronic diseases, a rapidly growing geriatric population, and a well-established pharmaceutical industry.

The United States leads the regional market due to strong clinical research activities, increasing demand for albumin in non-therapeutic applications, and advanced manufacturing capabilities. The presence of key market players and early adoption of innovative technologies further support market growth.

Asia Pacific (Fastest Growing Region)

Asia Pacific is expected to witness the fastest growth during the forecast period. Factors such as increasing healthcare expenditure, expanding pharmaceutical manufacturing, and rising demand for advanced therapeutics in countries like China, India, Japan, and Australia are driving regional growth.

Other Regions

• Europe: Strong regulatory framework and advanced healthcare infrastructure
• Latin America & Middle East & Africa: Gradual growth driven by improving healthcare access and investments

Why Buy This Report?

• Comprehensive insights into market size, growth trends, and forecasts through 2031
• Detailed analysis of key drivers, challenges, and opportunities
• In-depth profiling of major players and competitive strategies
• Segment-wise and region-wise market intelligence
• Strategic insights for investors, manufacturers, and stakeholders

Buy this Premium Research Report for exclusive, in-depth insights – https://www.transparencymarketresearch.com/checkout.php?rep_id=3984&ltype=S

FAQs

1. What is the current size of the albumin (as excipient) market?
   The market was valued at US$ 0.81 billion in 2021.
2. What is the projected market size by 2031?
   The market is expected to surpass US$ 1.7 billion by 2031.
3. What is the growth rate of the market?
   The market is projected to grow at a CAGR of 6.3% from 2022 to 2031.
4. Which region dominates the market?
   North America holds the largest market share.
5. What are the key drivers of the market?
   Key drivers include growth in pharmaceutical and biotechnology industries, increased use in drug delivery and vaccines, and rising demand for advanced therapeutics.

More Trending Reports by Transparency Market Research –

Vaccines Market: https://www.transparencymarketresearch.com/global-vaccine-market.html

Osteoporosis Drugs Market: https://www.transparencymarketresearch.com/osteoporosis-drug-market.html

Anti-Venom Market: https://www.transparencymarketresearch.com/anti-venom-market.html

Psychotropic Drugs Market: https://www.transparencymarketresearch.com/psychotropic-drugs-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com